Literature DB >> 16996720

Molecular and diagnostic aspects of genetic skin fragility.

Cristina Has1, Leena Bruckner-Tuderman.   

Abstract

Genetic syndromes with skin fragility represent a heterogeneous group of very rare disorders caused by mutations in genes encoding proteins or protein subunits important for the mechanical resistance of keratinocytes and for cell-cell or cell-extracellular matrix adhesion. The common symptoms are skin blistering or peeling, with various degrees of severity and distribution, ranging from localized to generalized forms. Associated features include involvement of skin annexes, mucous membranes, teeth, muscles or the digestive tract. Morphological investigation of skin samples provides evidence for the tissue level of blister formation, while immunostainings may reveal defective proteins, providing clues concerning the genetic origin of the disease. Extensive mutation analysis and subsequent identification of new gene defects provide accurate diagnostics, and lead to better understanding of the functions of the respective proteins, with the potential for new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16996720     DOI: 10.1016/j.jdermsci.2006.08.003

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  16 in total

Review 1.  The skinny on Slug.

Authors:  Stephanie H Shirley; Laurie G Hudson; Jing He; Donna F Kusewitt
Journal:  Mol Carcinog       Date:  2010-10       Impact factor: 4.784

2.  A novel large deletion mutation of FERMT1 gene in a Chinese patient with Kindler syndrome.

Authors:  Ying Gao; Jin-li Bai; Xiao-yan Liu; Yu-jin Qu; Yan-yan Cao; Jian-cai Wang; Yu-wei Jin; Hong Wang; Fang Song
Journal:  J Zhejiang Univ Sci B       Date:  2015-11       Impact factor: 3.066

Review 3.  [Epidermolysis bullosa. An update].

Authors:  H Schumann
Journal:  Hautarzt       Date:  2009-08       Impact factor: 0.751

4.  Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity.

Authors:  Johannes S Kern; Stefan Loeckermann; Anja Fritsch; Ingrid Hausser; Wera Roth; Thomas M Magin; Claudia Mack; Marcel L Müller; Oliver Paul; Patrick Ruther; Leena Bruckner-Tuderman
Journal:  Mol Ther       Date:  2009-06-30       Impact factor: 11.454

5.  [Epidermolysis bullosa : Diagnosis and therapy].

Authors:  C Has; L Bruckner-Tuderman
Journal:  Hautarzt       Date:  2011-02       Impact factor: 0.751

6.  Dynamic interactions of epidermal collagen XVII with the extracellular matrix: laminin 332 as a major binding partner.

Authors:  Wataru Nishie; Dimitra Kiritsi; Alexander Nyström; Silke C Hofmann; Leena Bruckner-Tuderman
Journal:  Am J Pathol       Date:  2011-06-14       Impact factor: 4.307

7.  Plakophilin 2 affects cell migration by modulating focal adhesion dynamics and integrin protein expression.

Authors:  Jennifer L Koetsier; Evangeline V Amargo; Viktor Todorović; Kathleen J Green; Lisa M Godsel
Journal:  J Invest Dermatol       Date:  2013-06-13       Impact factor: 8.551

8.  A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy.

Authors:  Anja Fritsch; Stefan Loeckermann; Johannes S Kern; Attila Braun; Michael R Bösl; Thorsten A Bley; Hauke Schumann; Dominik von Elverfeldt; Dominik Paul; Miriam Erlacher; Dirk Berens von Rautenfeld; Ingrid Hausser; Reinhard Fässler; Leena Bruckner-Tuderman
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

9.  Kindlin-1 Is required for RhoGTPase-mediated lamellipodia formation in keratinocytes.

Authors:  Cristina Has; Corinna Herz; Elena Zimina; Hai-Yan Qu; Yinghong He; Zhi-Gang Zhang; Ting-Ting Wen; Yannick Gache; Monique Aumailley; Leena Bruckner-Tuderman
Journal:  Am J Pathol       Date:  2009-09-17       Impact factor: 4.307

Review 10.  Biology and function of fetal and pediatric skin.

Authors:  Alice King; Swathi Balaji; Sundeep G Keswani
Journal:  Facial Plast Surg Clin North Am       Date:  2013-02       Impact factor: 1.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.